Arrowhead Pharmaceuticals, Inc.ARWR

Arrowhead Pharmaceuticals lost $132.7 million in the quarter to 31 March 2026 while booking $73.7 million of revenue, according to the freshly filed 10-Q. The net loss widened to $-141.3 million on an operating basis, the filings show, as research and development spending hit $173.3 million and the company’s short-term investments swelled to $1.60 billion. The cash position remains strong-$2.27 billion in assets with $1.60 billion of that in liquid securities-but the burn rate is the headline, not the balance sheet, because the only thing shareholders are being asked to finance today is more science, not more sales.

Arrowhead’s TRiM™ platform is positioned as a ‘robust and versatile drug discovery and development engine’ that uses ‘ligand-mediated delivery’ to target everything from cardiometabolic diseases to liver disorders. The company’s clinical trials page lists ongoing studies across a dozen programmes, but the filings do not disclose which, if any, are expected to read out positive in the next 12 months, nor do they quantify the probability of regulatory success for partnered programmes like the Sarepta and Novartis collaborations. The partnerships page promises milestone payments that could reach the low double digits in royalties and up to $700 million in sales-linked payments per programme, but those triggers remain contingent on the very science the 10-Q shows is still deeply in the red.

The company’s 10-Q for the quarter ending 31 March 2026 shows revenue of $73.7 million, a net loss of $132.7 million, and operating loss of $141.3 million, with R&D expense of $173.3 million and short-term investments of $1.60 billion. The diluted weighted average shares outstanding rose to 142.4 million, and net cash from operating activities was $97.9 million, offset by $4.7 million of capital expenditure. Stockholders’ equity stood at $614.0 million, while inventory increased by $451,000 in the prior quarter. Diluted earnings per share were $-0.93. (source: SEC EDGAR 10-Q (2026-05-07), https://www.sec.gov/Archives/edgar/data/879407/000087940726000047/arwr-20260331.htm)

Arrowhead Pharmaceuticals is a clinical-stage biotech focused on RNAi-based therapeutics using its TRiM™ platform for targeted delivery across liver, cardiometabolic, pulmonary, and neuromuscular diseases. The company’s public materials highlight partnerships with Sarepta and Novartis that include up to $700 million in sales milestone payments and tiered royalties on net sales, but these are contingent on Phase 3 outcomes and regulatory approvals that have not yet materialised. The clinical trials page lists multiple ongoing studies, including conditions that require nicotine abstinence for at least three months prior to screening, which suggests the company is not short on ambition-or bureaucracy. (source: Arrowhead Pharmaceuticals, Clinical Trials, https://www.arrowheadpharma.com/en-us/science-and-innovation/clinical-trials)

For a company with a $2.27 billion balance sheet, the current chart context matters less than the filing context: the gap between the valuation and the cash burn is the story. The SEC filings do not provide a forward-looking outlook, so the only concrete data points are the ones already cited: revenue, loss, cash, R&D spend, and shares outstanding. The company’s own disclosures do not allow investors to infer timing for near-term catalysts or the probability-weighted value of partnered programmes. If the next catalyst is a Phase 3 readout or an FDA action letter, that data is not yet in the public rail.

The company’s SEC EDGAR index and submissions JSON confirm the filings used above, but they do not add new numerical data beyond what is already captured in the 10-Q and related exhibits. The publications page lists peer-reviewed papers, the partnerships page flags milestone and royalty structures, and the science page describes the TRiM™ platform, but none of these sources provide updated financial guidance, revised probability tables, or concrete timelines for regulatory or commercial events. In short, the evidence rail gives us the filings and the platform story, while the market story remains a question mark.